Genmab Announces Financial Results for the First Half of 2026
Genmab reported H1 2026 revenue of $2.05 billion, up 25% year-over-year, driven by higher royalties from DARZALEX and Kesimpta and strong sales of EPKINLY. The company announced positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma, showing a statistically significant improvement in progression-free survival.
Key figures
- Revenue
- 2051000000
- Guidance
- Revenue $4.325B-$4.525B (raised from $4.065B-$4.395B); Adj Operating Profit $1.065B-$1.385B (raised from $900M-$1.4B)
- Revenue Yoy
- 25%
- Drug Name
- epcoritamab
- Phase Of Trial
- Phase 3
- Epkinly sales
- 312000000
- Royalty revenue
- 1708000000
- Operating profit
- 555000000
- Darzalex net sales
- 8171000000
- Adjusted operating profit
- 656000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.